Research & Development

Clinical-stage biopharmaceutical firm Antengene completes $120m Series B financing

Clinical-stage therapeutics company Antengene has raised $120m funding, which will be used to continue the development of its ATG-008 and ATG-010 (selinexor) and other clinical-stage assets.

Researchers conduct study to identify common genetic architecture of PCOS

International PCOS Consortium has carried out a study to determine the common genetic architecture for different diagnostic criteria that are employed to describe polycystic ovary syndrome (PCOS).

Scientists develop sight-saving treatment for eye infection

A group of scientists from the UK’s University of Birmingham has developed a new eye drop that can minimize sight-threatening scarring to the surface of the eye or the cornea.

Novartis offers to buy LFB group company CellforCure

Novartis has offered to acquire LFB group company CellforCure, which is specialized in the development of advanced therapy drugs.

Gilead, Agenus collaborate on immuno-oncology therapies development

Gilead Sciences and Agenus have entered into an immuno-oncology (I-O) partnership to develop and commercialize up to five novel immuno-oncology therapies.

Gilead, Scholar Rock to develop therapies for fibrotic diseases

Gilead Sciences and Scholar Rock have formed a collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.

DelSiTech, Innovare to develop long acting HIV therapy

Finland-based DelSiTech and Mexican pharma company Innovare R&D have signed a world-wide, exclusive license agreement for the use of the former’s Silica Matrix drug delivery platform in the development and commercialization of a long acting HIV therapy.

Amgen, Molecular Partners form immuno-oncology collaboration

Amgen and Molecular Partners have announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB).

Fuji Pharma acquires minority stake in Alvotech

Japan-based Fuji Pharma has acquired a 4.2% stake in biopharmaceutical firm Alvotech for around $50m.